Hepatitis B-Related Transverse Myelitis Prevalence
The prevalence of hepatitis B-related transverse myelitis is extremely rare, estimated at approximately 1 case per 600,000 to several million exposures, whether from vaccination or natural infection.
Vaccine-Associated Transverse Myelitis
The most comprehensive recent data comes from global pharmacovigilance analysis. Among 2,305 total vaccine-associated transverse myelitis reports identified from 1967-2023, hepatitis B vaccine showed a significant signal with a reported odds ratio of 38.04 for hepatitis A and similar ranges for hepatitis B vaccines 1. However, this represents passive surveillance data where the absolute incidence remains extraordinarily low, with a fatal outcome rate of only 0.22% among all vaccine-associated cases 1.
Key Epidemiological Points:
- Temporal relationship: Most vaccine-associated cases occur within days to 3 months post-vaccination, though longer intervals up to several years have been suggested 2
- Case reports: A systematic review identified only 37 total reported cases of transverse myelitis associated with various vaccines including hepatitis B between 1970-2009 2
- Historical context: The 1996 ACIP guidelines noted no established association between hepatitis B vaccination and severe neurological adverse events in large-scale immunization programs in Alaska, New Zealand, and Taiwan 3
Natural Hepatitis B Infection-Related Myelitis
Transverse myelitis from active hepatitis B infection is even rarer than vaccine-associated cases. The mechanism involves immune complex-mediated vasculitis, often with positive cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA) 4. These cases typically present with:
- Concurrent systemic manifestations (nephropathy, vasculitis)
- Evidence of active or chronic hepatitis B infection
- Autoimmune-mediated pathophysiology 4
Clinical Implications
The risk-benefit analysis overwhelmingly favors vaccination, as an estimated 2,000-5,000 persons in each U.S. birth cohort will die from HBV-related liver disease without vaccination 3. The theoretical risk of transverse myelitis (approximately 1 per million or less) is dwarfed by the 5% lifetime risk of HBV infection and its associated mortality 3.
Important Caveats:
- Age-related risk: Pharmacovigilance data suggests increased risk signals with advancing age, particularly in older adults 1
- Male predominance: Males may be more susceptible (43% of reported cases) 1
- Diagnostic challenge: Distinguishing post-vaccination myelitis from a first episode of multiple sclerosis depends on subsequent clinical course 5
- Recovery: Most reported cases show complete recovery within 3 months with corticosteroid treatment 6, 5
The increasing trend in vaccine-associated transverse myelitis reports after 2020 reflects COVID-19 vaccine surveillance rather than hepatitis B vaccines specifically 1. For hepatitis B specifically, the prevalence remains stable at extremely rare levels, with no change in the safety profile established over decades of use 3, 1.